利用MYC作为三阴性乳腺癌的一种治疗选择。 - Suppr

Leveraging MYC as a therapeutic treatment option for TNBC.

作者信息

Carey Jason P W, Keyomarsi Khandan

机构信息

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

Oncoscience. 2018 Jun 24;5(5-6):137-139. doi: 10.18632/oncoscience.424. eCollection 2018 May.

DOI:10.18632/oncoscience.424

PMID:30035166

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6049306/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/6049306/0a9e5bda6911/oncoscience-05-137-g001.jpg

相似文献

Leveraging MYC as a therapeutic treatment option for TNBC.利用MYC作为三阴性乳腺癌的一种治疗选择。

Oncoscience. 2018 Jun 24;5(5-6):137-139. doi: 10.18632/oncoscience.424. eCollection 2018 May.

SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.SPAG5 上调通过与三阴性乳腺癌中 c-MYC 结合蛋白相互作用促进 c-MYC 转录活性。

J Hematol Oncol. 2019 Feb 8;12(1):14. doi: 10.1186/s13045-019-0700-2.

New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.新型取代喹喔啉通过特异性地下调 c-MYC 转录抑制三阴性乳腺癌。

Nucleic Acids Res. 2019 Nov 18;47(20):10529-10542. doi: 10.1093/nar/gkz835.

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.抑制脂肪酸氧化作为治疗MYC过表达三阴性乳腺癌的一种方法。

Nat Med. 2016 Apr;22(4):427-32. doi: 10.1038/nm.4055. Epub 2016 Mar 7.

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.聚腺苷二磷酸核糖聚合酶抑制剂与 MYC 阻断联合应用的合成致死性不依赖于三阴性乳腺癌的 BRCA 状态。

Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.

mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.mTOR抑制剂抑制同源重组修复，并通过调控BRCA功能正常的三阴性乳腺癌中的SUV39H1与PARP抑制剂协同作用。

Clin Cancer Res. 2016 Apr 1;22(7):1699-712. doi: 10.1158/1078-0432.CCR-15-1772. Epub 2015 Nov 6.

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.DAXX 作为一种肿瘤抑制因子，影响 DNA 损伤修复，并使 BRCA 功能正常的三阴性乳腺癌细胞对 PARP 抑制剂敏感。

Neoplasia. 2019 Jun;21(6):533-544. doi: 10.1016/j.neo.2019.04.001. Epub 2019 Apr 24.

Long Noncoding RNA Promotes Cell Proliferation and Metastasis in Triple-negative Breast Cancer by Forming a Positive Regulatory Loop with miR-873-5p and MYC.长链非编码RNA通过与miR-873-5p和MYC形成正调控环促进三阴性乳腺癌细胞增殖和转移。

J Cancer. 2020 Jan 1;11(2):311-323. doi: 10.7150/jca.33982. eCollection 2020.

Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc.基于列线图模型联合HIF-1α和c-myc表达预测三阴性乳腺癌术后生存率

Medicine (Baltimore). 2019 Oct;98(40):e17370. doi: 10.1097/MD.0000000000017370.

Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.应用新一代测序技术重新定义三阴性乳腺癌的 BRCA 状态。

Cancer Sci. 2020 Apr;111(4):1375-1384. doi: 10.1111/cas.14313. Epub 2020 Feb 19.

引用本文的文献

Exploiting replication stress for synthetic lethality in MYC-driven cancers.利用复制应激实现MYC驱动癌症中的合成致死效应。

Am J Cancer Res. 2025 Apr 15;15(4):1461-1479. doi: 10.62347/RTVX8866. eCollection 2025.

Identification of novel prognostic genes of triple-negative breast cancer using meta-analysis and weighted gene co-expressed network analysis.使用荟萃分析和加权基因共表达网络分析鉴定三阴性乳腺癌的新型预后基因

Ann Transl Med. 2021 Feb;9(3):205. doi: 10.21037/atm-20-5989.

Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms.高级别神经内分泌宫颈癌的独特基因组格局：对重新思考当前治疗模式的启示

JCO Precis Oncol. 2020 Sep 3;4. doi: 10.1200/PO.19.00248. eCollection 2020.

本文引用的文献

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.BRD4 抑制通过诱导同源重组缺陷与 PARP 抑制剂协同致死。

Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.

Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.Myc通过调控炎症和免疫抑制与Ras协同作用。

Cell. 2017 Nov 30;171(6):1301-1315.e14. doi: 10.1016/j.cell.2017.11.013.

Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.表观遗传疗法将MYC缺失与逆转免疫逃逸及治疗肺癌联系起来。

Cell. 2017 Nov 30;171(6):1284-1300.e21. doi: 10.1016/j.cell.2017.10.022.

Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.PARP抑制剂上调PD-L1表达并增强癌症相关免疫抑制。

Clin Cancer Res. 2017 Jul 15;23(14):3711-3720. doi: 10.1158/1078-0432.CCR-16-3215. Epub 2017 Feb 6.

Poly(ADP-ribose) polymerase activity and inhibition in cancer.聚（ADP-核糖）聚合酶活性及其在癌症中的抑制作用。

Semin Cell Dev Biol. 2017 Mar;63:144-153. doi: 10.1016/j.semcdb.2017.01.007. Epub 2017 Jan 10.

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.CDK12抑制可逆转三阴性乳腺癌BRCA野生型和突变模型中的原发性和获得性PARP抑制剂耐药性。

Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.三阴性乳腺癌的演变：从生物学到新型疗法

Am Soc Clin Oncol Educ Book. 2016;35:34-42. doi: 10.1200/EDBK_159135.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Leveraging MYC as a therapeutic treatment option for TNBC.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献